CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 11 enrolled
Drug / intervention
isradipinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01658150
NCT01658150N/ACompleted
CompareCT.gov

A Molecular Approach to Treat Cognition in Schizophrenia: Ca2+ Channel Blockade

Icahn School of Medicine at Mount Sinai·interventional·Posted Aug 6, 2012·Updated Dec 5, 2018

In Brief

A clinical study evaluating isradipine for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 11 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the use of the drug isradipine for cognitive enhancement in patients diagnosed with schizophrenia and schizoaffective disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
CollaboratorsBrain & Behavior Research Foundation

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 6, 2012
Enrollment StartSep 1, 2012
Primary CompletionJan 2, 2018
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 13.9 years ago

Interventions

isradipinedrug

Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel